Biotheryx, Inc.

Biotheryx is a clinical-stage biopharmaceutical company focused on developing innovative small molecule targeted protein degraders (TPDs) for a variety of diseases, primarily cancer. The company leverages its proprietary PRODEGY platform, built on its expertise in Cereblon modulation, to design and develop first-in-class TPDs that have the potential to address significant unmet medical needs. Biotheryx's lead product candidate, BTX-1188, is a dual-targeting molecular glue degrader of GSPT1 and IKZF1/3 currently in a Phase 1/2 clinical trial for acute myeloid leukemia and solid tumor patients.

The company is driven by a purpose-driven team passionate about discovering and developing targeted protein degraders to address severe unmet patient needs. Biotheryx is actively building a broad and growing pipeline of degraders for various cancer targets, including SOS1 for KRAS mutant cancers and CDK2/4/6 for solid tumors, with the goal of submitting three additional investigational new drug (IND) applications to the FDA over the next three years.

Biotheryx is a biopharmaceutical company focused on discovering and developing first-in-class protein degraders, primarily for validated targets in cancer and inflammatory diseases. Their mission is to leverage their proprietary PRODEGY platform to address severe unmet patient needs by building a pipeline of targeted protein degraders, ultimately establishing themselves as a leader in next-generation targeted protein degradation.

Biotheryx promotes a purpose-driven culture focused on scientific innovation and a strong commitment to addressing unmet patient needs. The company values collaboration and scientific excellence, seeking to build a team of passionate individuals who are driven to develop life-saving medicines. This culture is evident in their dedication to leveraging their PRODEGY platform and developing a pipeline of first-in-class protein degraders.